{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T14:51:34Z","timestamp":1774536694335,"version":"3.50.1"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T00:00:00Z","timestamp":1648684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Epilepsy and depression are both serious and potentially disabling conditions which often coexist\u2014bidirectional relationship between the two disorders has been observed. Comorbidity between depression and epilepsy can be attributed to: underlying common pathophysiological mechanisms, psychiatric side effect of antiepileptic medications and psychological response to stress in people with chronic, neurological condition. Despite high prevalence of depressive symptoms in patients with epilepsy, current evidence of the effectiveness of antidepressant therapy in this group of patients is very limited. Vortioxetine is an antidepressant with multimodal activity, very good treatment tolerability, low risk of inducing pharmacokinetic interactions, relative safety of treatment in patients with somatic comorbidities, low risk of causing: sedation, sexual dysfunctions and metabolic side effects. Vortioxetine seems to be a promising treatment option for depressed patients with cognitive dysfunctions, anhedonia and anxiety. In this case series, we report nine cases of patients with epilepsy and depressive symptoms treated with vortioxetine. Seven cases are patients with secondary focal and generalized epilepsy and two with unclassified epilepsy. Three patients presented with depressive episode in the course of bipolar disorder and six patients had depressive symptoms due to organic mood disorder. The dose range of vortioxetine was between 10 and 20\u00a0mg. In all of the presented cases effectiveness and tolerability of treatment were very good. Remission of depressive symptoms was achieved in all patients. No epilepsy seizures after switch to vortioxetine were observed in seven cases. In two patients seizures occurred during the first months of vortioxetine treatment but this most probably was due to suboptimal antiepileptic treatment\u2014satisfactory seizure control was achieved after optimization of antiepileptic pharmacotherapy. Vortioxetine was discontinued in two of the presented cases due to pregnancy planning. The duration of observation period during vortioxetine therapy ranged from 2 to 48\u00a0months. In conclusion, vortioxetine can be a promising treatment option in patients with epilepsy and comorbid depressive symptoms.<\/jats:p>","DOI":"10.3389\/fphar.2022.852042","type":"journal-article","created":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T14:47:45Z","timestamp":1648738065000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Case Report: Vortioxetine in the Treatment of Depressive Symptoms in Patients With Epilepsy\u2014Case Series"],"prefix":"10.3389","volume":"13","author":[{"given":"Marcin","family":"Siwek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Gorostowicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Bosak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominika","family":"Dudek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.biopsych.2006.09.023","article-title":"Seizure Incidence in Psychopharmacological Clinical Trials: An Analysis of Food and Drug Administration (FDA) Summary Basis of Approval Reports","volume":"62","author":"Alper","year":"2007","journal-title":"Biol. Psychiatry"},{"key":"B2","doi-asserted-by":"publisher","first-page":"107797","DOI":"10.1016\/j.yebeh.2021.107797","article-title":"Vortioxetine Increases Absence-like Seizures in WAG\/Rij Rats but Decreases Penicillin- and Pentylenetetrazole-Induced Seizures in Wistar Rats","volume":"116","author":"Aygun","year":"2021","journal-title":"Epilepsy Behav."},{"key":"B3","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1177\/0269881116628440","article-title":"The Safety and Tolerability of Vortioxetine: Analysis of Data from Randomized Placebo-Controlled Trials and Open-Label Extension Studies","volume":"30","author":"Baldwin","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jad.2016.07.015","article-title":"A Meta-Analysis of the Efficacy of Vortioxetine in Patients with Major Depressive Disorder (MDD) and High Levels of Anxiety Symptoms","volume":"206","author":"Baldwin","year":"2016","journal-title":"J. Affect Disord."},{"key":"B5","doi-asserted-by":"publisher","first-page":"771","DOI":"10.3389\/fpsyt.2019.00771","article-title":"Vortioxetine for Cognitive Enhancement in Major Depression: From Animal Models to Clinical Research","volume":"1010","author":"Bennabi","year":"2019","journal-title":"Front. Psychiatry"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.pharep.2016.06.011","article-title":"Epilepsy Coexisting with Depression","volume":"68","author":"B\u0142aszczyk","year":"2016","journal-title":"Pharmacol. Rep."},{"key":"B7","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1111\/jcpt.13177","article-title":"Comparison of Vortioxetine and Sertraline for Treatment of Major Depressive Disorder in Elderly Patients: A Double-Blind Randomized Trial","volume":"45","author":"Borhannejad","year":"2020","journal-title":"J. Clin. Pharm. Ther."},{"key":"B8","first-page":"891","article-title":"Depresja U Chorych Z Padaczka [Depression in Patients with Epilepsy]","volume":"46","author":"Bosak","year":"2012","journal-title":"Psychiatr. Pol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.pjnns.2015.01.008","article-title":"Subtypes of Interictal Depressive Disorders According to ICD-10 in Patients with Epilepsy","volume":"49","author":"Bosak","year":"2015","journal-title":"Neurol. Neurochir Pol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"303","DOI":"10.20452\/pamw.14794","article-title":"Somatic Comorbidity in Polish Patients with Epilepsy","volume":"129","author":"Bosak","year":"2019","journal-title":"Pol. Arch. Intern. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.2147\/NDT.S91538","article-title":"Depressogenic Medications and Other Risk Factors for Depression Among Polish Patients with Epilepsy","volume":"11","author":"Bosak","year":"2015","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"B12","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.pjnns.2016.07.009","article-title":"Suicidality and its Determinants Among Polish Patients with Epilepsy","volume":"50","author":"Bosak","year":"2016","journal-title":"Neurol. Neurochir Pol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3389\/fpsyt.2019.00017","article-title":"The Efficacy of Vortioxetine on Anhedonia in Patients with Major Depressive Disorder","volume":"10","author":"Cao","year":"2019","journal-title":"Front. Psychiatry"},{"key":"B14","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.yebeh.2017.08.039","article-title":"Psychiatric and Behavioral Side Effects of Antiepileptic Drugs in Adults with Epilepsy","volume":"76","author":"Chen","year":"2017","journal-title":"Epilepsy Behav."},{"key":"B15","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s40262-017-0612-7","article-title":"Vortioxetine: Clinical Pharmacokinetics and Drug Interactions","volume":"57","author":"Chen","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","article-title":"Comparative Efficacy and Acceptability of 21 Antidepressant Drugs for the Acute Treatment of Adults with Major Depressive Disorder: a Systematic Review and Network Meta-Analysis","volume":"391","author":"Cipriani","year":"2018","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1177\/0269881115581093","article-title":"Evidence-based Guidelines for Treating Depressive Disorders with Antidepressants: A Revision of the 2008 British Association for Psychopharmacology Guidelines","volume":"29","author":"Cleare","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"B18","first-page":"36","article-title":"Vortioxetine (Brintellix): A New Serotonergic Antidepressant","volume":"40","author":"D\u2019Agostino","year":"2015","journal-title":"P T"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1080\/14656566.2021.1880567","article-title":"Vortioxetine in Management of Major Depressive Disorder - a Favorable Alternative for Elderly Patients?","volume":"22","author":"Danielak","year":"2021","journal-title":"Expert Opin. Pharmacother."},{"key":"B20","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.seizure.2016.10.018","article-title":"Diagnosing and Treating Depression in Epilepsy","volume":"44","author":"Elger","year":"2017","journal-title":"Seizure"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1016\/S0140-6736(13)60899-5","article-title":"Premature Mortality in Epilepsy and the Role of Psychiatric Comorbidity: A Total Population Study","volume":"382","author":"Fazel","year":"2013","journal-title":"Lancet"},{"key":"B22","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/epi.12550","article-title":"ILAE Official Report: A Practical Clinical Definition of Epilepsy","volume":"55","author":"Fisher","year":"2014","journal-title":"Epilepsia"},{"key":"B23","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/epi.13670","article-title":"Operational Classification of Seizure Types by the International League against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Fisher","year":"2017","journal-title":"Epilepsia"},{"key":"B24","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.eplepsyres.2014.11.003","article-title":"Prevalence of Depressive Symptoms and Their Impact on Quality of Life in Patients with Drug-Resistant Focal Epilepsy (IMDYVA Study)","volume":"110","author":"Garcia","year":"2015","journal-title":"Epilepsy Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1002\/epi4.12367","article-title":"Refractory Epilepsy and Nonadherence to Drug Treatment","volume":"4","author":"Henning","year":"2019","journal-title":"Epilepsia Open"},{"key":"B26","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1001\/jamapsychiatry.2015.2516","article-title":"Occurrence and Recurrence of Attempted Suicide Among People with Epilepsy","volume":"73","author":"Hesdorffer","year":"2016","journal-title":"JAMA Psychiatry"},{"key":"B27","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.eplepsyres.2007.06.003","article-title":"Predictors of Pharmacoresistant Epilepsy","volume":"75","author":"Hitiris","year":"2007","journal-title":"Epilepsy Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1684\/epd.2015.0739","article-title":"Cognitive Impairment in Epilepsy: The Role of Network Abnormalities","volume":"17","author":"Holmes","year":"2015","journal-title":"Epileptic Disord."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1111\/jsm.12980","article-title":"Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction","volume":"12","author":"Jacobsen","year":"2015","journal-title":"J. Sex. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1017\/S1092852915000553","article-title":"Treatment-emergent Sexual Dysfunction in Randomized Trials of Vortioxetine for Major Depressive Disorder or Generalized Anxiety Disorder: A Pooled Analysis","volume":"21","author":"Jacobsen","year":"2016","journal-title":"CNS Spectr."},{"key":"B31","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1111\/j.0013-9580.2004.47003.x","article-title":"The Relative Impact of Anxiety, Depression, and Clinical Seizure Features on Health-Related Quality of Life in Epilepsy","volume":"45","author":"Johnson","year":"2004","journal-title":"Epilepsia"},{"key":"B32","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1001\/jamaneurol.2016.5042","article-title":"Association of Depression and Treated Depression with Epilepsy and Seizure Outcomes: A Multicohort Analysis","volume":"74","author":"Josephson","year":"2017","journal-title":"JAMA Neurol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1212\/01.wnl.0000343850.85763.9c","article-title":"A Lifetime Psychiatric History Predicts a Worse Seizure Outcome Following Temporal Lobectomy","volume":"72","author":"Kanner","year":"2009","journal-title":"Neurology"},{"key":"B34","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/j.1535-7511.2009.01294.x","article-title":"Suicidality and Epilepsy: A Complex Relationship that Remains Misunderstood and Underestimated","volume":"9","author":"Kanner","year":"2009","journal-title":"Epilepsy Curr."},{"key":"B35","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/S1474-4422(15)00225-2","article-title":"Comorbidities of Epilepsy: Current Concepts and Future Perspectives","volume":"15","author":"Keezer","year":"2016","journal-title":"Lancet Neurol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"E47","DOI":"10.1097\/HTR.0000000000000439","article-title":"The Effect of Antidepressants on Depression after Traumatic Brain Injury: A Meta-Analysis","volume":"34","author":"Kreitzer","year":"2019","journal-title":"J. Head Trauma Rehabil."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of Drug Resistant Epilepsy: Consensus Proposal by the Ad Hoc Task Force of the ILAE Commission on Therapeutic Strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"key":"B38","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3988\/jcn.2014.10.3.175","article-title":"Depression and Anxiety in People with Epilepsy","volume":"10","author":"Kwon","year":"2014","journal-title":"J. Clin. Neurol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/bcp.13772","article-title":"Preliminary Evidence that Vortioxetine May Improve Sleep Quality in Depressed Patients with Insomnia: a Retrospective Questionnaire Analysis","volume":"85","author":"Liguori","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"CD010682","DOI":"10.1002\/14651858.CD010682.pub2","article-title":"Antidepressants for People with Epilepsy and Depression","volume":"4","author":"Maguire","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"B41","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1185\/03007995.2012.761600","article-title":"A Randomized, Double-Blind Trial of 2.5 Mg and 5 Mg Vortioxetine (Lu AA21004) versus Placebo for 8 Weeks in Adults with Major Depressive Disorder","volume":"29","author":"Mahableshwarkar","year":"2013","journal-title":"Curr. Med. Res. Opin."},{"key":"B42","doi-asserted-by":"publisher","first-page":"a022798","DOI":"10.1101\/cshperspect.a022798","article-title":"Common Mechanisms Underlying Epileptogenesis and the Comorbidities of Epilepsy","volume":"6","author":"Mazarati","year":"2016","journal-title":"Cold Spring Harb Perspect. Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1080\/14737175.2019.1585244","article-title":"Developments in Depression in Epilepsy: Screening, Diagnosis, and Treatment","volume":"19","author":"Mula","year":"2019","journal-title":"Expert Rev. Neurother"},{"key":"B44","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1590\/0004-282X20190064","article-title":"The Effect of Vortioxetine on Penicillin-Induced Epileptiform Activity in Rats","volume":"77","author":"\u00d6g\u00fcn","year":"2019","journal-title":"Arq Neuropsiquiatr"},{"key":"B45","doi-asserted-by":"publisher","first-page":"88","DOI":"10.4103\/aian.AIAN_291_17","article-title":"Recovery of Visual Scotomas by Vortioxetine in a Patient with Symptomatic Occipital Lobe Epilepsy","volume":"21","author":"Onder","year":"2018","journal-title":"Ann. Indian Acad. Neurol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"e7218","DOI":"10.1590\/1414-431x20187218","article-title":"Efficacy, Acceptability, and Tolerability of Antidepressant Treatments for Patients with post-stroke Depression: A Network Meta-Analysis","volume":"51","author":"Qin","year":"2018","journal-title":"Braz. J. Med. Biol. Res."},{"key":"B47","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE Classification of the Epilepsies: Position Paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.12740\/pp\/onlinefirst\/132962","article-title":"A Naturalistic, 24-week, Open-Label, Add-On Study of Vortioxetine in Bipolar Depression","author":"Siwek","year":"2021","journal-title":"Psychiatr. Pol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"451","DOI":"10.3390\/ph14050451","article-title":"Withdrawal Symptoms Following Discontinuation of Vortioxetine-Retrospective Chart Review","volume":"14","author":"Siwek","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"B50","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1055\/s-0043-117962","article-title":"Epileptic Seizures under Antidepressive Drug Treatment: Systematic Review","volume":"51","author":"Steinert","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1080\/14737175.2016.1204233","article-title":"The Comorbidity of Epilepsy and Depression: Diagnosis and Treatment","volume":"16","author":"Tao","year":"2016","journal-title":"Expert Rev. Neurother"},{"key":"B52","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1684\/epd.2021.1344","article-title":"Vortioxetine Suppresses Epileptiform Activity and Cognition Deficits in a Chronic PTZ-Induced Kindling Rat Model","volume":"23","author":"Taskiran","year":"2021","journal-title":"Epileptic Disord."},{"key":"B53","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1111\/j.1528-1167.2011.03213.x","article-title":"Predictors of Health-Related Quality of Life and Costs in Adults with Epilepsy: A Systematic Review","volume":"52","author":"Taylor","year":"2011","journal-title":"Epilepsia"},{"key":"B54","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1111\/j.1528-1167.2007.01222.x","article-title":"Psychiatric Comorbidity in Epilepsy: A Population-Based Analysis","volume":"48","author":"Tellez-Zenteno","year":"2007","journal-title":"Epilepsia"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.852042\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T14:47:50Z","timestamp":1648738070000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.852042\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,31]]},"references-count":54,"alternative-id":["10.3389\/fphar.2022.852042"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.852042","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,31]]},"article-number":"852042"}}